Valerio Therapeutics SA 2017 IR
The report outlines Onxeo's strategic and operational developments in 2017, highlighting the advancement of its key oncology programs, AsiDNA and belinostat, following the suspension of the Livatag program. The company successfully raised 15 million euros and divested non-strategic assets to optimize resources. Onxeo's sustainability disclosures emphasize its commitment to workplace health and safety, professional gender equality, and employee development. Additionally, the company implemented a workforce reduction plan to control costs while maintaining its core research and development capabilities.
Company: Valerio Therapeutics SA
Sector: Professional & technical services
Country: France
Year: 2017
Type: IR
Pages: 205
Back to company
Valerio Therapeutics SA
Registration Document
The report outlines Onxeo's strategic and operational developments in 2017, highlighting the advancement of its key oncology programs, AsiDNA and belinostat, following the suspension of the Livatag program. The company successfully raised 15 million euros and divested non-strategic assets to optimize resources. Onxeo's sustainability disclosures emphasize its commitment to workplace health and safety, professional gender equality, and employee development. Additionally, the company implemented a workforce reduction plan to control costs while maintaining its core research and development capabilities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Published
Apr 25, 2018
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Employees